Article
Clinical Neurology
Marcus W. Koch, Jop Mostert, Pavle Repovic, James D. Bowen, Bernard Uitdehaag, Gary Cutter
Summary: The study compared the frequency of progression and improvement events in SPMS trials using data from the placebo arms of two large RCTs. The EDSS showed the highest rates of improvement over time, with the smallest difference between progression and improvement rates, followed by the T25FW and 9HPT. The findings suggest random variation and measurement error in all investigated outcome measures, with the T25FW and 9HPT showing less than the more established outcome measure EDSS.
Review
Clinical Neurology
Bruce A. C. Cree, Douglas L. Arnold, Jeremy Chataway, Tanuja Chitnis, Robert J. Fox, Angela Pozo Ramajo, Niamh Murphy, Hans Lassmann
Summary: In most cases, multiple sclerosis begins with a relapsing-remitting course followed by secondary progressive MS (SMPS), and there are major differences between RRMS and SPMS in terms of treatment response and diagnosis. However, clear criteria marking the transition from RRMS to SPMS have not been established yet. Early identification of SPMS will require tools that, along with appropriate treatment, may lead to better long-term outcomes.
Article
Clinical Neurology
Alice Mariottini, Giovanni Bulgarini, Benedetta Forci, Chiara Innocenti, Fabrizia Mealli, Alessandra Mattei, Chiara Ceccarelli, Anna Maria Repice, Alessandro Barilaro, Claudia Mechi, Riccardo Saccardi, Luca Massacesi
Summary: The study demonstrates that for patients with secondary-progressive multiple sclerosis (SP-MS), AHSCT is more effective than cyclophosphamide (Cy) in reducing relapse activity, but there is no significant difference between the two in terms of disability progression. AHSCT is beneficial for reducing relapses, but disability progression in SP-MS is more likely driven by noninflammatory neurodegeneration.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Article
Clinical Neurology
Sam Harding-Forrester, Izanne Roos, Ai-Lan Nguyen, Charles B. Malpas, Ibrahima Diouf, Nahid Moradi, Sifat Sharmin, Guillermo Izquierdo, Sara Eichau, Francesco Patti, Dana Horakova, Eva Kubala Havrdova, Alexandre Prat, Marc Girard, Pierre Duquette, Francois Grand Maison, Marco Onofrj, Alessandra Lugaresi, Pierre Grammond, Serkan Ozakbas, Maria Pia Amato, Oliver Gerlach, Patrizia Sola, Diana Ferraro, Katherine Buzzard, Olga Skibina, Jeannette Lechner-Scott, Raed Alroughani, Cavit Boz, Vincent Van Pesch, Elisabetta Cartechini, Murat Terzi, Davide Maimone, Cristina Ramo-Tello, Bassem Yamout, Samia Joseph Khoury, Daniele La Spitaleri, Maria Jose Sa, Yolanda Blanco, Franco Granella, Mark Slee, Ernest Butler, Youssef Sidhom, Riadh Gouider, Roberto Bergamaschi, Rana Karabudak, Radek Ampapa, Jose Luis Sanchez-Menoyo, Julie Prevost, Tamara Castillo-Trivino, Pamela A. McCombe, Richard Macdonell, Guy Laureys, Liesbeth Van Hijfte, Jiwon Oh, Ayse Altintas, Koen de Gans, Recai Turkoglu, Anneke van der Walt, Helmut Butzkueven, Steve Vucic, Michael Barnett, Edgardo Cristiano, Suzanne Hodgkinson, Gerardo Iuliano, Ludwig Kappos, Jens Kuhle, Vahid Shaygannejad, Aysun Soysal, Bianca Weinstock-Guttman, Bart Van Wijmeersch, Tomas Kalincik
Summary: This study compared primary and secondary progressive multiple sclerosis (PPMS, SPMS), and found that SPMS has later onset of the progressive phase and slower disability accrual, but higher baseline disability.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Clinical Neurology
Jamie K. Wong, Jerry Lin, Nathan J. Kung, Alexandra L. Tse, Serena J. E. Shimshak, Anna K. Roselle, Francesca M. Cali, Jessie Huang, Joseph M. Beaty, Taylor M. Shue, Saud A. Sadiq
Summary: Multiple sclerosis can present as relapsing-remitting or progressive forms. It is unclear whether these forms represent the same disease or distinct entities with similar pathological features. This study provides evidence that primary progressive multiple sclerosis is characterized by a unique capacity of cerebrospinal fluid (CSF) to induce motor disability and spinal cord pathology, which can be attenuated by removing immunoglobulin G from the CSF. Injection of recombinant antibodies derived from primary progressive multiple sclerosis CSF reproduces the pathology, suggesting an antibody-mediated and distinct pathogenic mechanism for this form of the disease. These findings have important implications for developing targeted therapies for primary progressive multiple sclerosis patients.
Article
Clinical Neurology
Matilde Oviedo Querejazu, Nicky Dunn, Ryan Ramanujam, Malin Ryner, Michael Auer, Poul Erik Hyldgaard Jensen, Florian Deisenhammer, Anna Fogdell-Hahn, A. B. I. R. I. S. K. consortium Behalf ABIRISK consortium
Summary: This study found a low frequency of transient and fluctuating positive neutralizing anti-drug antibodies (NAbs) in the treatment of multiple sclerosis, which is important for clinical decision-making.
MULTIPLE SCLEROSIS AND RELATED DISORDERS
(2022)
Article
Clinical Neurology
Marcus W. Koch, Jop Mostert, Pavle Repovic, James D. Bowen, Bernard Uitdehaag, Gary Cutter
Summary: The study found that in patients with SPMS, SDMT scores steadily increased over a 2-year follow-up period, with overall few SDMT worsening events occurring throughout the trial. Additionally, PASAT scores exhibited a similar pattern of change as SDMT.
EUROPEAN JOURNAL OF NEUROLOGY
(2021)
Article
Clinical Neurology
Winston Dzau, Sifat Sharmin, Francesco Patti, Guillermo Izquierdo, Sara Eichau, Alexandre Prat, Marc Girard, Pierre Duquette, Marco Onofrj, Alessandra Lugaresi, Serkan Ozakbas, Oliver Gerlach, Cavit Boz, Pierre Grammond, Murat Terzi, Maria Pia Amato, Daniele La Spitaleri, Cristina Ramo-Tello, Davide Maimone, Elisabetta Cartechini, Katherine Buzzard, Olga Skibina, Anneke van der Walt, Helmut Butzkueven, Gerardo Iuliano, Aysun Soysal, Tomas Kalincik
Summary: This study investigated the association between early progression independent of relapse activity (PIRA) and relapse-associated worsening (RAW) with the onset and disability accumulation of secondary progressive multiple sclerosis (SPMS). It found that early PIRA and RAW were associated with increased risk of SPMS, but not with the rate of disability progression during SPMS.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
(2023)
Article
Multidisciplinary Sciences
Ben J. E. Raveney, Wakiro Sato, Daiki Takewaki, Chenyang Zhang, Tomomi Kanazawa, Youwei Lin, Tomoko Okamoto, Manabu Araki, Yukio Kimura, Noriko Sato, Terunori Sano, Yuko Saito, Shinji Oki, Takashi Yamamura
Summary: This study identified a subset of cytotoxic CD4(+) T cells expressing Eomes, known as Eomes(+) Th cells, that are crucially involved in the pathogenesis of secondary progressive MS (SPMS). Eomes levels could act as a biomarker to predict disease worsening in SPMS patients with over 80% accuracy. These findings have significant implications for SPMS biomarkers and potential therapeutic targets.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Clinical Neurology
Ralph H. B. Benedict, Davorka Tomic, Bruce A. Cree, Robert Fox, Gavin Giovannoni, Amit Bar-Or, Ralf Gold, Patrick Vermersch, Harald Pohlmann, Ian Wright, Goril Karlsson, Frank Dahlke, Christian Wolf, Ludwig Kappos
Summary: The study shows that siponimod has a significant benefit on cognitive processing speed in patients with secondary progressive multiple sclerosis. Siponimod-treated patients were at significantly lower risk for a >= 4-point decrease in SDMT score and had a significantly higher chance for a >= 4-point increase, which is considered clinically meaningful.
Article
Neurosciences
Forough Foolad, Zahra Samadi-Bahrami, Fariba Khodagholi, Seyed Massood Nabavi, G. R. Wayne Moore, Mohammad Javan
Summary: This study suggests that mitochondrial dysfunction and alterations in some epigenetics and metabolism modifying factors in the CNS and peripheral blood cells may contribute to or correlate with the progression of multiple sclerosis.
MOLECULAR NEUROBIOLOGY
(2023)
Article
Clinical Neurology
Ralf Gold, Daniela Piani-Meier, Ludwig Kappos, Amit Bar-Or, Patrick Vermersch, Gavin Giovannoni, Robert J. Fox, Douglas L. Arnold, Ralph H. B. Benedict, Iris-Katharina Penner, Nicolas Rouyrre, Ajay Kilaru, Goril Karlsson, Shannon Ritter, Frank Dahlke, Thomas Hach, Bruce A. C. Cree
Summary: The study found that siponimod reduced the risk of disability progression and had positive effects on cognition and MRI outcomes in patients with active secondary progressive multiple sclerosis.
JOURNAL OF NEUROLOGY
(2022)
Review
Clinical Neurology
Sarah B. Simmons, Sven Schippling, Gavin Giovannoni, Daniel Ontaneda
Summary: In addition to well-known clinical predictors, smoking, obesity, vascular and psychiatric comorbidities are associated with subsequent disability worsening in persons with MS. Various imaging features can predict disability worsening and are present to varying degrees in different forms of MS. Recent studies show promise in utilizing neurofilament light as easily attainable biomarkers for future disability accumulation.
CURRENT OPINION IN NEUROLOGY
(2021)
Article
Clinical Neurology
Izanne Roos, Emmanuelle Leray, Romain Casey, Dana Horakova, Eva Havrdova, Guillermo Izquierdo, Sara Eichau Madueno, Francesco Patti, Gilles Edan, Marc Debouverie, Jean Pelletier, Serkan Ozakbas, Maria Pia Amato, Pierre Clavelou, Pierre Grammond, Cavit Boz, Katherine Buzzard, Olga Skibina, Jonathan Ciron, Oliver Gerlach, Francois Grand'Maison, Jeannette Lechner-Scott, Charles Malpas, Helmut Butzkueven, Sandra Vukusic, Tomas Kalincik, PGCertBiostat, MSBase and OFSEP Study Grp
Summary: High-efficacy therapy is more effective in reducing relapses in patients with active SPMS compared to low-efficacy therapy, but no difference was observed in relapse frequency between the two therapies in patients with inactive SPMS. There was no evidence for a difference in disability progression risk between high- and low-efficacy therapies in treated patients with SPMS.
Article
Clinical Neurology
Izanne Roos, Emmanuelle Leray, Romain Casey, Dana Horakova, Eva Havrdova, Guillermo Izquierdo, Sara Eichau Madueno, Francesco Patti, Gilles Edan, Marc Debouverie, Jean Pelletier, Serkan Ozakbas, Maria Pia Amato, Pierre Clavelou, Pierre Grammond, Cavit Boz, Katherine Buzzard, Olga Skibina, Jonathan Ciron, Oliver Gerlach, Francois Grand'Maison, Jeannette Lechner-Scott, Charles Malpas, Helmut Butzkueven, Sandra Vukusic, Tomas Kalincik
Summary: The study found that high-efficacy therapy is more effective in reducing relapse frequency in patients with active SPMS compared to low-efficacy therapy, but no significant difference was observed in patients with inactive SPMS. There was also no difference in disability progression between the two groups of patients.
Article
Ophthalmology
Kengadhevi Yogeswaran, Joao M. Furtado, Bahram Bodaghi, Janet M. Matthews, Justine R. Smith
Summary: Ocular toxoplasmosis is a common global infection. This study provides an overview of the current management approach for ocular toxoplasmosis based on a survey completed by uveitis-specialised ophthalmologists from 48 countries. The findings include clinical features, diagnostic methods, treatment options, and follow-up practices. The majority of respondents used clinical examination and serology for diagnosis, and oral trimethoprim-sulfamethoxazole was the most commonly used first-line therapy. Follow-up and prophylaxis against recurrence were also discussed.
BRITISH JOURNAL OF OPHTHALMOLOGY
(2023)
Letter
Clinical Neurology
Emilio Portaccio, Maria Pia Amato
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Medical Laboratory Technology
Ulf Andreasson, Johan Gobom, Vincent Delatour, Guy Auclair, Yoav Noam, Stephen Lee, Jason Wen, Andreas Jeromin, Burak Arslan, Aleksandra Maceski, Eline Willemse, Henrik Zetterberg, Jens Kuhle, Kaj Blennow
Summary: This study determined the best certified reference material (CRM) for neurofilament light chain (NfL) in blood by analyzing 40 paired serum and plasma samples. The results showed that using cerebrospinal fluid (CSF) for sample validation was more accurate than using recombinant human NfL protein, and serum was a better choice than plasma as the matrix for a CRM.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Alexandra Ramona Todea, Lester Melie-Garcia, Muhamed Barakovic, Alessandro Cagol, Reza Rahmanzadeh, Riccardo Galbusera, Po-Jui Lu, Matthias Weigel, Esther Ruberte, Ernst-Wilhelm Radue, Sabine Schaedelin, Pascal Benkert, Yaldizli Oezguer, Tim Sinnecker, Stefanie Mueller, Lutz Achtnichts, Jochen Vehoff, Giulio Disanto, Oliver Findling, Andrew Chan, Anke Salmen, Caroline Pot, Patrice Lalive, Claire Bridel, Chiara Zecca, Tobias Derfuss, Luca Remonda, Franca Wagner, Maria Vargas, Renaud Du Pasquier, Emanuele Pravata, Johannes Weber, Claudio Gobbi, David Leppert, Jens Wuerfel, Tobias Kober, Benedicte Marechal, Ricardo Corredor-Jerez, Marios Psychogios, Johanna Lieb, Ludwig Kappos, Meritxell Bach Cuadra, Jens Kuhle, Cristina Granziera
Summary: This study evaluated the accuracy of LeMan-PV software for detecting new and enlarged white matter lesions in multiple sclerosis patients. The results showed that LeMan-PV had similar sensitivity in detecting new lesions compared to other recent studies using neural networks. Although its performance is not optimal, the main advantage of LeMan-PV is that it provides automated clinical decision support integrated into the routine radiological workflow.
JOURNAL OF MAGNETIC RESONANCE IMAGING
(2023)
Article
Clinical Neurology
Carmen Cananau, Yngve Forslin, Asa Bergendal, Henrik Sjostrom, Katharina Fink, Russell Ouellette, Maria Kristoffersen Wiberg, Sten Fredrikson, Tobias Granberg
Summary: This study aimed to investigate the associations between prior gadolinium administrations and MT and T1 signal abnormalities. The results showed dose-dependent associations between conventional T1-weighted imaging and gadolinium administrations, but these associations could not be detected with 2D MT. Future studies could explore newer MT techniques like 3D and inhomogenous MT.
JOURNAL OF NEUROIMAGING
(2023)
Article
Clinical Neurology
Alessandro Cagol, Nuria Cerda Fuertes, Marc Stoessel, Muhamed Barakovic, Sabine Schaedelin, Marcus D'Souza, Jens Wurfel, Alexander U. Brandt, Ludwig Kappos, Till Sprenger, Yvonne Naegelin, Jens Kuhle, Cristina Granziera, Athina Papadopoulou
Summary: This study investigated the associations among OCT changes, MRI measurements of brain volume loss, and physical and cognitive impairment in patients with multiple sclerosis. The results showed that OCT measures of pRNFL and GCIPL were associated with volumes of gray matter structures, and inversely correlated with T2-lesion volume. These findings highlight the value of OCT as markers of neurodegeneration and disability in multiple sclerosis.
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Nils G. Margraf, Justina Dargvainiene, Emily Theel, Frank Leypoldt, Wolfgang Lieb, Andre Franke, Klaus Berger, Jens Kuhle, Gregor Kuhlenbaeumer
Summary: This study investigates the potential of neurofilament light chain (NfL) in serum and cerebrospinal fluid as a biomarker for neurodestruction in status epilepticus. The results suggest that the concentration of NfL is mainly determined by the duration of status epilepticus, rather than the type of status or treatment refractoriness.
JOURNAL OF NEUROLOGY
(2023)
Article
Clinical Neurology
Valentin Loser, Pascal Benkert, Alex Vicino, Pansy Lim Dubois Ferriere, Thierry Kuntzer, Jerome Pasquier, Aleksandra Maceski, Jens Kuhle, Marie Theaudin
Summary: Serum neurofilament light chain (sNfL) may serve as an early and reliable biomarker of peripheral neuropathy in hATTR amyloidosis, allowing for assessment of disease severity and treatment response.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM
(2023)
Article
Clinical Neurology
Charidimos Tsagkas, Antal Huck-Horvath, Alessandro Cagol, Tanja Haas, Muhamed Barakovic, Michael Amann, Esther Ruberte, Lester Melie-Garcia, Matthias Weigel, Simon Pezold, Regina Schlaeger, Jens Kuhle, Till Sprenger, Ludwig Kappos, Oliver Bieri, Philippe Cattin, Cristina Granziera, Katrin Parmar
Summary: Spinal cord atrophy of the cervical anterior horn is clinically relevant in multiple sclerosis (MS) patients, particularly in progressive MS (PMS) patients and at the level of cervical SC enlargement.
MULTIPLE SCLEROSIS JOURNAL
(2023)
News Item
Clinical Neurology
Maria Pia Amato, Emilio Portaccio
Summary: The first randomized, placebo-controlled trial of dimethyl fumarate in radiologically isolated syndrome patients demonstrated its efficacy in reducing the risk of a first clinical demyelinating event. These findings provide a foundation for preventive medicine in multiple sclerosis and underscore the importance of precise risk prognostication.
NATURE REVIEWS NEUROLOGY
(2023)
Article
Health Care Sciences & Services
Markus Siegel, Lisa Bode, Leonard Simon Brandenburg, Andreas Frodl, Hagen Schmal, Jan Kuehle
Summary: This study retrospectively analyzed 31 adult patients to examine the use and effects of autologous and xenogeneic bone grafts in foot surgery. The results showed that although xenogeneic grafts had a lower incorporation rate, they did not increase the risk of hindfoot alignment loss in the first six months after surgery.
JOURNAL OF PERSONALIZED MEDICINE
(2023)
Article
Clinical Neurology
R. Veldkamp, M. D'hooge, B. M. Sandroff, J. DeLuca, D. Kos, A. Salter, A. Feinstein, M. P. Amato, G. Brichetto, J. Chataway, R. Farrell, N. D. Chiaravalloti, U. Dalgas, M. Filippi, J. Freeman, R. W. Motl, C. Meza, M. Inglese, M. A. Rocca, G. Cutter, P. Feys
Summary: Performing cognitive-motor dual tasks can negatively affect walking performance and cognitive function in individuals with progressive multiple sclerosis and cognitive impairment. This study examined the dual task performance in different disability levels and found that it significantly affected walking performance, with similar effects across disability subgroups.
JOURNAL OF NEUROLOGY
(2023)
Review
Clinical Neurology
Susana Otero-Romero, Christine Lebrun-Frenay, Saul Reyes, Maria Pia Amato, Magda Campins, Mauricio Farez, Massimo Filippi, Yael Hacohen, Bernhard Hemmer, Rosa Juuti, Melinda Magyari, Celia Oreja-Guevara, Aksel Siva, Sandra Vukusic, Mar Tintore
Summary: This study aims to develop an evidence-based vaccination strategy for pwMS who are candidates for disease-modifying therapies. A multidisciplinary working group conducted a systematic literature search and formulated 53 recommendations based on the quality of evidence. The goal of this study is to homogenize immunization practices in pwMS.
MULTIPLE SCLEROSIS JOURNAL
(2023)
Editorial Material
Clinical Neurology
Matilde Inglese, Maria Pia Amato
MULTIPLE SCLEROSIS JOURNAL
(2023)
Article
Gastroenterology & Hepatology
Lindsay Devolder, Ayla Pauwels, Ann Van Remoortel, Gwen Falony, Sara Vieira-Silva, Guy Nagels, Jacques De Keyser, Jeroen Raes, Marie B. D'Hooghe
Summary: This study investigated the relationship between gut microbial composition and long-term disability worsening in 111 MS patients. The results showed that the inflammation-associated, dysbiotic Bacteroides 2 enterotype (Bact2) was more prevalent in patients with worsening disability compared to non-worsened patients. This association was independent of confounding factors and Bact2 showed a stronger association with disability worsening than neurofilament light chain (NfL) plasma levels. Additionally, Bact2 was relatively stable over time, suggesting its potential use as a prognostic biomarker in MS clinical practice.